Home › Acute Myeloid Leukemia › NCT05875805
A Telehealth Advance Care Planning Intervention
A Telehealth Advance Care Planning Intervention for Older Patients With Myeloid Malignancies: A Pilot Randomized Controlled Trial
Who can join
Ages 60 and older · All sexes
Full eligibility criteria
Inclusion and Exclusion Criteria for Patients Inclusion criteria: * Age ≥60 years * A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS/MPN overlap syndrome, myelofibrosis) * Being managed in the outpatient settings * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Caregivers Inclusion criteria: * Age ≥18 years * Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters" * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Oncology Providers Inclusion criteria: \- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit Exclusion criteria: \- None
About the study
The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.
What is being tested
- Telehealth Serious Illness Care Program (behavioral)
- Education Control (other)
Sponsor: University of Rochester · Participants: 207 · Started: May 20, 2024
Contact the study team
- Kah Poh Loh, MD · Phone: 585-276-4353
- Becky Gravenstede · Phone: 585-727-4728
Official record on ClinicalTrials.gov — NCT05875805
Locations in the U.S.
| New York | University of Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.